DNA Vaccines

DNA-Mediated Immunization Addresses Chronic Hepatitis B Carrier State

Published in Gene Therapy Weekly, December 9th, 1996

Successful DNA-mediated immunization in a transgenic murine model of hepatitis B surface antigen chronic carrier state suggests the potential of this method to treat chronic human hepatitis B virus (HBV) carriers.

Following initial infection with HBV, some individuals fail to resolve their infection and become chronic carriers. The proportion of HBV-infected chronic carriers is estimated between 5-20 percent of those infected as adults and as high as 95 percent in infants who were infected perinatally. There are estimated to be more than 250 million chronic HBV carriers in the world today. Persistent HBV infection is associated with liver cirrhosis and hepatocellular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry